Exosomes and Renal Fibrosis: Diagnostic Value, Therapeutic Potential and Challenges.

IF 6.5 2区 医学 Q1 NANOSCIENCE & NANOTECHNOLOGY
International Journal of Nanomedicine Pub Date : 2025-09-13 eCollection Date: 2025-01-01 DOI:10.2147/IJN.S529311
Yumeng Li, Yousuf Abdulkarim Waheed, Dong Sun
{"title":"Exosomes and Renal Fibrosis: Diagnostic Value, Therapeutic Potential and Challenges.","authors":"Yumeng Li, Yousuf Abdulkarim Waheed, Dong Sun","doi":"10.2147/IJN.S529311","DOIUrl":null,"url":null,"abstract":"<p><p>Renal fibrosis is a key pathological process in the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD), characterised by irreversible damage to the renal parenchyma. Currently, effective curative treatments are lacking. Exosomes, double-layer phospholipid vesicles containing bioactive components such as proteins, lipids, and nucleic acids, play a pivotal role in intercellular communication. Under physiological conditions, exosomes contribute to kidney development (eg regulating of ureteric bud branching and nephron formation) and maintenance of cellular homeostasis (eg protection of the glomerular filtration barrier and regulation of electrolyte balance). In pathological conditions, damaged renal tubular epithelial cells (RTECs) and other renal cell types release exosomes carrying pro-fibrotic factors (eg miR-21, TGF-β), which activate fibroblasts and facilitate excessive extracellular matrix (ECM) deposition, thereby accelerating the fibrotic process. Exosomes possess significant diagnostic value, as their protein components (eg Cp and CD2AP in urinary exosomes) and RNA cargo (eg lncRNA, miRNA, circRNA) may serve as biomarkers for renal function impairment. Therapeutically, exosomes derived from bone marrow, adipose tissue, umbilical cord, and urine can delay fibrosis through multiple mechanisms, including anti-inflammatory effects, antioxidant activity, promotion of angiogenesis, and regulation of signalling pathways (eg NOTCH, AKT). Engineered exosomes exhibit enhanced targeting and delivery efficiency through endogenous or exogenous loading methods, thereby further improving therapeutic efficacy. However, current research faces challenges including inconsistent methods of exosome isolation and purification, absence of standardised identification protocols, insufficient stability, and barriers to clinical translation. This review summarises the current progress in exosome research related to renal fibrosis, covering physiological and pathological roles, diagnostic and therapeutic potential, and existing challenges, aiming to facilitate translation from basic research to clinical practice and to provide novel strategies for precise diagnosis and treatment of renal fibrosis.</p>","PeriodicalId":14084,"journal":{"name":"International Journal of Nanomedicine","volume":"20 ","pages":"11267-11294"},"PeriodicalIF":6.5000,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12442909/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Nanomedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJN.S529311","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"NANOSCIENCE & NANOTECHNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Renal fibrosis is a key pathological process in the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD), characterised by irreversible damage to the renal parenchyma. Currently, effective curative treatments are lacking. Exosomes, double-layer phospholipid vesicles containing bioactive components such as proteins, lipids, and nucleic acids, play a pivotal role in intercellular communication. Under physiological conditions, exosomes contribute to kidney development (eg regulating of ureteric bud branching and nephron formation) and maintenance of cellular homeostasis (eg protection of the glomerular filtration barrier and regulation of electrolyte balance). In pathological conditions, damaged renal tubular epithelial cells (RTECs) and other renal cell types release exosomes carrying pro-fibrotic factors (eg miR-21, TGF-β), which activate fibroblasts and facilitate excessive extracellular matrix (ECM) deposition, thereby accelerating the fibrotic process. Exosomes possess significant diagnostic value, as their protein components (eg Cp and CD2AP in urinary exosomes) and RNA cargo (eg lncRNA, miRNA, circRNA) may serve as biomarkers for renal function impairment. Therapeutically, exosomes derived from bone marrow, adipose tissue, umbilical cord, and urine can delay fibrosis through multiple mechanisms, including anti-inflammatory effects, antioxidant activity, promotion of angiogenesis, and regulation of signalling pathways (eg NOTCH, AKT). Engineered exosomes exhibit enhanced targeting and delivery efficiency through endogenous or exogenous loading methods, thereby further improving therapeutic efficacy. However, current research faces challenges including inconsistent methods of exosome isolation and purification, absence of standardised identification protocols, insufficient stability, and barriers to clinical translation. This review summarises the current progress in exosome research related to renal fibrosis, covering physiological and pathological roles, diagnostic and therapeutic potential, and existing challenges, aiming to facilitate translation from basic research to clinical practice and to provide novel strategies for precise diagnosis and treatment of renal fibrosis.

Abstract Image

Abstract Image

Abstract Image

外泌体和肾纤维化:诊断价值、治疗潜力和挑战。
肾纤维化是慢性肾脏疾病(CKD)发展为终末期肾脏疾病(ESRD)的关键病理过程,其特征是肾实质的不可逆损伤。目前,缺乏有效的治疗方法。外泌体是含有蛋白质、脂质和核酸等生物活性成分的双层磷脂囊泡,在细胞间通讯中起着关键作用。生理条件下,外泌体参与肾脏发育(如调节输尿管芽分支和肾元形成)和维持细胞稳态(如保护肾小球滤过屏障和调节电解质平衡)。在病理状态下,受损的肾小管上皮细胞(RTECs)和其他肾细胞类型释放携带促纤维化因子(如miR-21、TGF-β)的外泌体,激活成纤维细胞,促进细胞外基质(ECM)过度沉积,从而加速纤维化过程。外泌体具有重要的诊断价值,因为它们的蛋白质成分(如尿外泌体中的Cp和CD2AP)和RNA货物(如lncRNA、miRNA、circRNA)可能是肾功能损害的生物标志物。在治疗方面,来自骨髓、脂肪组织、脐带和尿液的外泌体可以通过多种机制延缓纤维化,包括抗炎作用、抗氧化活性、促进血管生成和调节信号通路(如NOTCH、AKT)。工程外泌体通过内源性或外源性负载方式表现出更高的靶向性和递送效率,从而进一步提高治疗效果。然而,目前的研究面临的挑战包括外泌体分离和纯化方法不一致,缺乏标准化的鉴定方案,稳定性不足以及临床翻译的障碍。本文综述了肾纤维化相关外泌体的生理病理作用、诊断和治疗潜力以及存在的挑战等方面的研究进展,旨在促进从基础研究到临床实践的转化,为肾纤维化的精确诊断和治疗提供新的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Journal of Nanomedicine
International Journal of Nanomedicine NANOSCIENCE & NANOTECHNOLOGY-PHARMACOLOGY & PHARMACY
CiteScore
14.40
自引率
3.80%
发文量
511
审稿时长
1.4 months
期刊介绍: The International Journal of Nanomedicine is a globally recognized journal that focuses on the applications of nanotechnology in the biomedical field. It is a peer-reviewed and open-access publication that covers diverse aspects of this rapidly evolving research area. With its strong emphasis on the clinical potential of nanoparticles in disease diagnostics, prevention, and treatment, the journal aims to showcase cutting-edge research and development in the field. Starting from now, the International Journal of Nanomedicine will not accept meta-analyses for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信